Predictors of mortality in patients under treatment for chronic hepatitis B in Ethiopia: a prospective cohort study

Autor: Nega Berhe, Hailemichael Desalegn, Asgeir Johannessen, Hanna Aberra, Bitsatab Mekasha, Girmay Medhin, Svein Gunnar Gundersen
Jazyk: angličtina
Rok vydání: 2019
Předmět:
Adult
Liver Cirrhosis
Male
medicine.medical_specialty
Time Factors
Survival
Adolescent
Epidemiology
Physical examination
Antiviral therapy
Antiviral Agents
Body Mass Index
03 medical and health sciences
Young Adult
0302 clinical medicine
Hepatitis B
Chronic
Interquartile range
Risk Factors
Internal medicine
Medicine
Humans
Prospective Studies
lcsh:RC799-869
Prospective cohort study
Tenofovir
Proportional Hazards Models
medicine.diagnostic_test
business.industry
Hazard ratio
Gastroenterology
Age Factors
General Medicine
Hepatitis B
Hepatology
Middle Aged
medicine.disease
Resource-limited settings
Survival Rate
VDP::Medisinske Fag: 700::Helsefag: 800
030220 oncology & carcinogenesis
lcsh:Diseases of the digestive system. Gastroenterology
030211 gastroenterology & hepatology
Female
Ethiopia
business
Body mass index
Research Article
Zdroj: BMC Gastroenterology
BMC Gastroenterology, Vol 19, Iss 1, Pp 1-7 (2019)
Popis: Background Antiviral treatment for chronic hepatitis B (CHB) is largely unavailable in sub-Saharan Africa; hence, little is known about the prognosis after initiating treatment in African CHB patients. In this study we aimed to assess predictors of mortality in one of the largest CHB cohorts in sub-Saharan Africa. Methods Two-hundred-and-seventy-six CHB patients who started treatment with tenofovir disoproxil fumarate at a public hospital in Ethiopia between March 18, 2015, and August 1, 2017, were included in this analysis. Patients were followed up until October 1, 2017, and deaths were ascertained through hospital records and telephone interview with relatives. Decompensated cirrhosis was defined as current or past evidence of ascites, either by clinical examination or by ultrasonography. Cox proportional hazard models were used to identify independent predictors of mortality. Results Thirty-five patients (12.7%) died during follow-up, 33 of whom had decompensated cirrhosis at recruitment. The median duration from start of treatment to death was 110 days (interquartile range 26–276). The estimated survival was 90.3, 88.2 and 86.3% at 6, 12 and 24 months of follow-up, respectively. Independent predictors of mortality were decompensated cirrhosis (adjusted hazard ratio [AHR] 23.68; 95% CI 3.23–173.48; p = 0.002), body mass index
Databáze: OpenAIRE
Externí odkaz: